Dolor Technologies has entered a settlement agreement to resolve false claims allegations relating to a device it sold to treat migraines.
From July 2013 to July 2017, the company allegedly caused medical providers to submit false claims to Medicare for the device, according to a Dec. 11 news release from the Justice Department.
The device, SphenoCath, was intended to treat migraines by administering nerve blocks. The government alleges the device was not approved by the FDA for use in nerve blocks to treat headaches.
The government also alleges Dolor instructed medical providers to submit improper Medicare billing codes.
The company is required to repay the government based on its ability to pay.